Experience

Replicate Bioscience, Inc.

• United States
• Biotechnology
• 1 - 100 Employee

• Compound Development Team Lead

  • May 2022 - Present



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Translational Lead - Cancer Vaccines and Immunotherapeutics

  • Apr 2021 - May 2022



The Janssen Pharmaceutical Companies of Johnson & Johnson

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Research Project Lead - RNA Vaccines

  • May 2019 - Apr 2021

  • Led the srRNA Immunology team (consisting of 2 senior associate scientists and a PhD level scientist) to generate all self-replicating RNA vaccine discovery and preclinical translational datasets for IND • Led the development of a shared neoantigen srRNA vaccine for hematological malignancies. Managing a matrixed team consisting of molecular biology, CMC, pharmacology and clinical sub-teams to produce IND-enabling datasets • Led a pharmacology sub-team to design and generate discovery and preclinical datasets for the development of therapeutic vaccines for a chronic viral infection Evaluated lipid nanoparticle (LNP) formulations in vivo to optimize RNA vaccine immunogenicity • Managed contracting and planning with CROs to perform in vivo experiments • Conducted deep-dives into competitor assets to compare with the Janssen portfolio to determine business development strategy for disease area strongholds Show less



Viridos

• United States
• Biotechnology Research
• 1 - 100 Employee

• Oncology Vaccines Lead

  • Apr 2018 - May 2019

  Project leader responsible for creating the oncology vaccine program and developing preclinical candidates including the presentation of the overall strategy, identification of vaccine targets, development of animal models and design of proof-of-concept studies Planned pre-IND studies to develop internal oncology vaccine products Managing a team of up to 4 direct reports as well as managing additional reports and teams in a matrixed environment. Attended the Center for Creative Leadership training course on Maximizing Leadership Potential Led in vivo immunogenicity and efficacy studies to develop a self-replicating RNA vaccine platform to target tumor-associated antigens and neoantigens as well as evaluating the effect of synergy with immune modulators during vaccination Collaborated with multiple pharmaceutical and biotech companies as well as KOLs to build proof-of- concept datasets for oncology vaccine targets Collaborated with multiple CROs and internal business development and legal teams Show less



Fate Therapeutics Inc

• United States
• Biotechnology Research
• 200 - 300 Employee

• Scientist - Immuno-oncology

  • Jan 2016 - Apr 2018

  • Reported directly to the Senior Director of R&D to develop small molecule drug candidates for use in CAR T cell tumor immunotherapy. This project was in collaboration with Juno Therapeutics and included frequent presentation of data and future strategies • Initiated and developed novel in vivo tumor models to measure persistence, efficacy and exhaustion of human CAR T cells • Additional research areas included investigation of the MOA of clinical candidate therapy, ProTmune™, to prevent acute GvHD during hematopoietic stem cell transplantation and preclinical development of IPSC-derived regulatory cells for immunotherapy of autoimmune disease • Managed 1 direct report Show less



Scripps Research

• United States
• Research Services
• 700 & Above Employee

• Postdoc - Immunology

  • Mar 2010 - Jan 2016

  I worked in the Laboratory of Dr. Linda Sherman. I investigated the role of the autoimmunity-associated gene, PTPN22, in immune tolerance and applied these findings to viral infection and tumor immunotherapy I worked in the Laboratory of Dr. Linda Sherman. I investigated the role of the autoimmunity-associated gene, PTPN22, in immune tolerance and applied these findings to viral infection and tumor immunotherapy